Document is current
Any future updates will be listed below
-
Authors
de la Peña, Francisco Ayala https://orcid.org/0000-0001-6311-920X
Novoa, Silvia Antolín
Gregori, Joaquín Gavilá
Cortijo, Lucía González
Carrasco, Fernando Henao
Martínez Martínez, María Teresa
Estévez, Cristina Morales
Stradella, Agostina
Losada, María Jesús Vidal
Ciruelos, Eva
-
Funding
Funding for this research was provided by:
Sociedad Española de Oncología Médica
- License Information
-
More Information
Article History
Received: 5 November 2025
Accepted: 9 November 2025
First Online: 29 November 2025
Declarations
:
: Francisco Ayala de la Peña has received fees for speaking and participating in advisory boards from AstraZeneca, Novartis, Lilly, Sanofi, Daichii Sankyo, Celgene, Eisai, Pierre Fabre, Pfizer, Roche, MSD, and Seagen. Joaquín Gavilá Gregori has received fees for speaking and participating in advisory boards from Daiichi Sankyo, AstraZeneca, Novartis, Roche, Pfizer, and Lilly. Fernando Henao Carrasco has received fees for participating in advisory boards from AstraZeneca, Daiichi-Sankyo, Novartis, Pfizer, Lilly, and Roche. Agostina Stradella has received fees for speaking and participating in advisory boards from AstraZeneca, Daiichi-Sankyo, Novartis, MSD and Gilead. Eva Ciruelos has received fees for speaking and participating in advisory boards from Roche, Lilly, Pfizer, AstraZeneca, Daichii Sankyo, Novartis, MSD, Gilead, and Reveal Genomics. Silvia Antolín Novoa, Lucía González Cortijo, María Teresa Martínez Martínez, Cristina Morales Estévez, and María Jesús Vidal Losada declare that they have no conflicts of interest.
: Not applicable. The manuscript does not contain clinical studies or patient data.
